Stocks:
5,472
ETFs:
2,400
Exchanges:
11
Market Cap:
$58.99T
24h Vol:
$9.82B
Dominance:
MSFT:5.13%
Stocklytics Platform
BETA
Instrument logo  APLS

Apellis Pharmaceuticals Inc

APLS
64 / 100
High Growth
$71.73arrow_drop_up4.76%$3.26

Performance History

Stocklytics logo
Key Stats
Open$68.79
Prev. Close$68.47
EPS-5.23
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$8.50B
PE Ratio-
LOWHIGH
Day Range68.08
71.89
52 Week Range19.83
94.75
Ratios
P/B Ratio34.95
Revenue$272.87M
Operating M. %-115.11%
Earnings$0.00
Earnings Growth %7.07%
EBITDA Margin %-218.03%
ROE %-224.59%
EPS-5.23

Score Breakdown

64vs 53. Market Avg.

All Score 64 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

APLSMARKET
Value2739
Quality5140
Ownership019
Growth8046
Dividends-37
check_circle

Apellis Pharmaceuticals Inc's Price growth average in the last 3 years of 15.54% is great compared to market average of 6.82%. This indicates APLS could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$771.91
24H (%)arrow_drop_up0.30%
24H ($)$2.38
MARKET CAP$733.45B
PRICE$525.32
24H (%)arrow_drop_down-0.36%
24H ($)-$1.91
MARKET CAP$485.88B
PRICE$160.78
24H (%)arrow_drop_down-0.64%
24H ($)-$1.05
MARKET CAP$387.30B
PRICE$128.84
24H (%)arrow_drop_down-0.47%
24H ($)-$0.61
MARKET CAP$326.48B

About Apellis Pharmaceuticals Inc (APLS)

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA). The company also develops APL-2006, a bispecific C3 and VEGF inhibitor for treating wet age-related macular degeneration and GA; APL-1030, a C3 inhibitor for the treatment of various neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Cedric Francois M.D., Ph.D.
Headquarters
Waltham
Employees
767
Exchange
NASDAQ
add Apellis Pharmaceuticals Inc to watchlist

Keep an eye on Apellis Pharmaceuticals Inc

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
question_mark
What is Apellis Pharmaceuticals Inc's (APLS) price per share?

The current price per share for Apellis Pharmaceuticals Inc (APLS) is $71.73. The stock has seen a price change of $3.26 recently, indicating a 4.76% change. This reflects the stock's recent market performance and investor sentiment.

question_mark
What is the 52-week high and low for Apellis Pharmaceuticals Inc (APLS)?

For Apellis Pharmaceuticals Inc (APLS), the 52-week high is $94.75, which is 32.09% from the current price. The 52-week low is $19.83, the current price is 261.72% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

question_mark
Is Apellis Pharmaceuticals Inc (APLS) a growth stock?

Apellis Pharmaceuticals Inc (APLS) has shown an average price growth of 15.54% over the past three years. It has received a score of 78 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Apellis Pharmaceuticals Inc as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

question_mark
What is Apellis Pharmaceuticals Inc (APLS) stock price performance year to date (YTD)?

As of the latest data, Apellis Pharmaceuticals Inc (APLS) has a year-to-date price change of 17.09%. Over the past month, the stock has experienced a price change of 11.9%. Over the last three months, the change has been 48.45%. Looking at a longer horizon, the five-year price change stands at 394.69%.

question_mark
Is Apellis Pharmaceuticals Inc (APLS) a profitable company?

Apellis Pharmaceuticals Inc (APLS) has a net income of -$606.04M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 84.78% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -115.11% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $272.88M, although specific revenue growth data is currently not available. The gross profit is $231.35M. Operating income is noted at -$596.66M. Furthermore, the EBITDA is -$594.96M.

question_mark
What is the market capitalization of Apellis Pharmaceuticals Inc (APLS)?

Apellis Pharmaceuticals Inc (APLS) has a market capitalization of $8.5B. The average daily trading volume is 1.08M, indicating the stock's liquidity and investor engagement.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.